<DOC>
	<DOCNO>NCT01213680</DOCNO>
	<brief_summary>The purpose study assess pharmakokinetic property higher dos ( 500 mg 1000 mg ) Monofer ( R ) patient suffer inflammatory bowel disease</brief_summary>
	<brief_title>Open-label PK Study Iron Isomaltoside 1000 ( Monofer ) Administered 500 mg IV Injection 1000 mg IV Infusion Patients With Inflammatory Bowel Disease</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Men woman , age 18 year 2 . Subjects diagnose inflammatory bowel disease mild moderate disease activity ( define score less equal 5 HarveyBradshaw index Crohn 's disease Mayo score ( subscore without endoscopy ) less equal 6 ulcerative colitis ) 3 . Weight 50 kg 4 . Hb &lt; 12 g/dL ( 7.45 mmol/L ) 5 . Transferrin saturation ( TfS ) &lt; 20 % 6 . Life expectancy beyond 12 month investigator 's judgment 7 . Willingness participate inform consent 1 . Anaemia predominantly cause factor iron deficiency anaemia 2 . Iron overload disturbance utilisation iron ( e.g . haemochromatosis haemosiderosis ) 3 . Drug hypersensitivity ( i.e . previous hypersensitivity Iron Dextran iron mono disaccharide complex iron sulphate ) 4 . Known hypersensitivity excipients investigational drug product 5 . Subjects history multiple allergy 6 . Active Intestinal Tuberculosis 7 . Active intestinal amoebic infection 8 . Decompensated liver cirrhosis hepatitis ( Alanine Aminotransferase ( ALT ) &gt; 3 time upper limit normal ) 9 . History immunocompromise and/or history Hepatitis B and/or C 10 . Acute infection ( assessed clinical judgment ) , support white blood cell ( WBC ) Creactive protein ( CRP ) ) 11 . Rheumatoid arthritis symptom sign active joint inflammation 12 . Pregnancy nursing ( To avoid pregnancy , woman postmenopausal ( least 12 month must elapse since last menstruation ) , surgically sterile , woman child bear potential must use one follow contraceptive whole study period study end least 5 time plasma biological halflife investigational medicinal product : Contraceptive pill , intrauterine device ( IUD ) , contraceptive depot injection ( prolongedrelease gestagen ) , subdermal implantation , vaginal ring , transdermal patch ) 13 . Extensive active bleeding necessitate blood transfusion 14 . Planned elective surgery study 15 . Participation clinical study within 3 month prior screen 16 . Untreated B12 folate deficiency 17 . Other I.V . oral iron treatment blood transfusion within 4 week prior screen visit 18 . Erythropoietin treatment within 4 week prior screen visit 19 . Any medical condition , opinion Investigator , may cause patient unsuitable completion study place patient potential risk study . Example : Uncontrolled Hypertension , Unstable Ischemic Heart Disease Uncontrolled Diabetes Mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Inflammatory Bowel Disease , IBD</keyword>
</DOC>